The Lyon healthcare cluster is mobilizing alongside our #VirPath laboratory in its fight against SARS-CoV-2.
The Lyon healthcare cluster is mobilizing alongside our #VirPath laboratory in its fight against SARS-CoV-2. In collaboration with the Hospices Civils de Lyon, the genomic platform ProfileXpert and the companies ViroScan3D and Signia Therapeutics, our laboratory has isolated and characterized by deep sequencing two SARS-CoV-2 viral strains from several patient samples. Our analyses confirm that our SARS-CoV2 viral bank is genetically stable after amplification at both the consensus level and the low-frequency mutation landscape. Sequences have been uploaded to GISAID to contribute to the international program monitoring and studying the SARS-CoV-2.
The BIOTECHFINANCES magazine highlighted the work of Signia Therapeutics and VirPath to fight against the coronavirus "2019-nCoV".
Glycoflu program aims to develop a new generation of influenza antiviral drugs.
Our VirPath Laboratory, with its technological research Platform VirNext, is partner of the GlycoFlu program which aims to develop a new generation of influenza drugs that could be administered orally (aerosols) with multiple development potentials (human or avian flu) and applications both prophylactic and therapeutic. Launched on January 20, 2020, this program funded by the SATT Linksium Grenoble Alpes, is led by Emeline Richard Millot, winner of the Grand Prize in the I-PhD competition from the Ministry of Higher Education, Research and Innovation in partnership with BPI France, and Eric Samain from CERMAV (CNRS). #influenza #antiviral
The Agence France-Presse (AFP) dispatch about VirPath is quoted by french and international newspapers.
Video reportages of Agence France-Presse (AFP).
"VirPath, a university laboratory in Lyon, is working to find an effective treatment for the novel coronavirus using an existing database of drugs."
Our laboratory VIRPATH is mobilized with the REACTING consortium on the front line against the 2019-n-CoV Coronavirus
We are currently characterizing the virus in several preclinical models of interest with the aim of applying our drug repurposing strategy and thus rapidly proposing a therapeutic solution to be tested in clinic against such new emerging epidemic virus. Signia Therapeutics joins our laboratory in the fight against Coronavirus 2019-n-CoV and announces that two proprietary molecules from its portfolio, already validated for their antiviral properties against MERS-COV and several other human and animal coronaviruses, will be tested against Coronavirus 2019-n-CoV in preclinical models of infection.
In Lyon, the VirPath laboratory tries to find a treatment against 2019-nCoV.
Dr Manuel ROSA-CALATRAVA has been interviewed by France 3 Auvergne Rhône Alpes about the novel coronavirus. He explained that the VirPath laboratory was focused on finding a treatment for coronavirus using existing drugs.
INSERM press room : "Deadly outbreak in China linked to a novel form of coronavirus"
Inserm is already mobilized to respond to the epidemic, under the action of the Reacting consortium, which brings together French research groups of excellence. Several initiatives have been launched:
- The work entrusted to Bruno Lina (Inserm Unit 1111 – Centre International de Recherche en Infectiologie, CIRI) to propose a research project on potential therapeutic targets to identify molecules capable of acting on several types of coronavirus.
Map of Chinese provinces colour coded according to the number of cases of 2019-nCoV  as at 27 January 2020. Credits Vittoria Colizza
Launch of Cynbiome network
VirPath: We are pleased to announce the launch of Cynbiome, a preclinical excellence network on microbiome and infectious diseases. We congratulate the principal investigator Cynbiose, a service company specializing in the development and commercialization of innovative preclinical models.
Our laboratory and our Technological Research Platform VirNext are very proud to be partners of the cynbiome network. We will bring our expertises, OMICS analytic tools and biological materials in the field of infectious diseases to contribute in the development of this ambitious and unique network in EU.
Our last editorial just published in John Libbey Eurotext Virologie concerning Novel antiviral compounds and combination therapy for influenza viruses.
Notre éditorial dans Virologie, la revue officielle de la Société Française de Virologie, sur les Nouveaux antiviraux et thérapie combinée contre les virus influenza.